News headlines about Cerner (NASDAQ:CERN) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cerner earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.0694599694384 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s rankings:
- Northeastern Health System selects Cerner for health care IT (tahlequahdailypress.com)
- BidaskClub Lowers Cerner (CERN) to Hold (americanbankingnews.com)
- ETFs with exposure to Cerner Corp. : December 21, 2017 (finance.yahoo.com)
- Rite Aid Corporation (RAD) Mix Thrust In Focus with, Cerner Corporation (CERN) – Investing News Update (investingbizz.com)
- FY2017 Earnings Estimate for Cerner Co. Issued By SunTrust Banks (CERN) (americanbankingnews.com)
Cerner (CERN) traded down $0.51 during trading hours on Monday, hitting $67.38. 2,514,600 shares of the company were exchanged, compared to its average volume of 2,355,209. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.77 and a quick ratio of 2.75. The company has a market cap of $22,230.00, a PE ratio of 33.52, a PEG ratio of 2.20 and a beta of 0.94. Cerner has a 52 week low of $47.09 and a 52 week high of $73.86.
CERN has been the topic of several recent analyst reports. Canaccord Genuity reissued a “buy” rating and set a $69.00 target price on shares of Cerner in a research report on Wednesday, September 6th. JPMorgan Chase & Co. cut shares of Cerner from an “overweight” rating to a “neutral” rating in a research report on Friday, October 27th. Stifel Nicolaus reissued a “hold” rating on shares of Cerner in a research report on Wednesday, November 22nd. Piper Jaffray Companies reissued a “buy” rating and set a $77.00 target price on shares of Cerner in a research report on Thursday, October 12th. Finally, Royal Bank of Canada reissued a “buy” rating on shares of Cerner in a research report on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nine have given a buy rating to the company. Cerner has an average rating of “Hold” and a consensus target price of $69.50.
In related news, President Zane M. Burke sold 50,000 shares of Cerner stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $70.00, for a total value of $3,500,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael R. Battaglioli sold 4,000 shares of Cerner stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $69.89, for a total transaction of $279,560.00. Following the completion of the transaction, the vice president now owns 4,000 shares of the company’s stock, valued at $279,560. The disclosure for this sale can be found here. Insiders sold a total of 788,000 shares of company stock valued at $52,190,800 over the last quarter. 13.11% of the stock is owned by company insiders.
Cerner Company Profile
Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT). The Company offers a range of intelligent solutions and services that support the clinical, financial and operational needs of organizations of all sizes. The Company’s segments include Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States.
Receive News & Ratings for Cerner Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner and related companies with MarketBeat.com's FREE daily email newsletter.